Acute Ischemic Stroke Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Acute Ischemic Stroke pipeline constitutes 35+ key companies continuously working towards developing 35+ Acute Ischemic Stroke treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Acute Ischemic Stroke Overview
Acute Ischemic Stroke occurs when blood flow through a brain artery is blocked by a clot- a mass of thickened blood. Clots are either thrombotic or embolic, depending on where they develop within the body. A thrombotic stroke, more common of the two, occurs when a clot forms within an artery in the brain. Almost half of all acute ischemic strokes are due to large vessel occlusion (LVO).

"Acute Ischemic Stroke Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Ischemic Stroke Market.

The Acute Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Acute Ischemic Stroke Pipeline Report https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

• Companies across the globe are diligently working toward developing novel Acute Ischemic Stroke treatment therapies with a considerable amount of success over the years. Acute Ischemic Stroke Key players such as - Prolong Pharmaceuticals, Meridigen Biotech, Techfields Pharma, Biogen, Shin Poong Pharmaceutical, NuvOx LLC, Acticor Biotech, Acticor Biotech, Athersys, NoNO, and others, are developing therapies for the Acute Ischemic Stroke treatment
• Acute Ischemic Stroke Emerging therapies such as - PP 007, UMC 119 06, TF 0023, BIIB131, SP-8203, NVX-108, Glenzocimab, Invimestrocel, Nerinetide, and others are expected to have a significant impact on the Acute Ischemic Stroke market in the coming years.
• In Octomber 2016, Arbor Vita Corporation, a U.S.-based biotechnology company, and NoNO, Inc biotechnologycompany focused on neurological diseases, announced their partnership for the development and commercializationof drugs for the treatment of stroke
• In March 2017, NoNO Inc initiated a Phase III, multicentre, randomized, double-blinded,placebo-controlled, parallel group, single-dose design to determine the efficacy and safety of intravenousna-1 in subjects with acute ischemic stroke undergoing endovascular thrombectomy
• In December 2020, NoNO Inc initiated a multicenter, randomized, double-blinded, placebo-controlled, parallel group, single-dose design to determine the efficacy and safety of Nerinetide in participants with acute ischemic stroke undergoing endovascular thrombectomy excluding thrombolysis

Acute Ischemic Stroke Pipeline Therapeutics Assessment
• Acute Ischemic Stroke Assessment by Product Type
• Acute Ischemic Stroke By Stage and Product Type
• Acute Ischemic Stroke Assessment by Route of Administration
• Acute Ischemic Stroke By Stage and Route of Administration
• Acute Ischemic Stroke Assessment by Molecule Type
• Acute Ischemic Stroke by Stage and Molecule Type

DelveInsight's Acute Ischemic Stroke Report covers around 35+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Acute Ischemic Stroke Drugs Under Different Phases of Clinical Development Include:
• PP 007: Prolong Pharmaceuticals
• UMC 119 06: Meridigen Biotech
• TF 0023: Techfields Pharma
• BIIB131: Biogen
• SP-8203: Shin Poong Pharmaceutical
• NVX-108: NuvOx LLC
• Glenzocimab: Acticor Biotech
• Invimestrocel: Athersys
• Nerinetide: NoNO

Get a Free Sample PDF Report to know more about Acute Ischemic Stroke Pipeline Assessment- https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acute Ischemic Stroke Pipeline Analysis:

The Acute Ischemic Stroke pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Acute Ischemic Stroke treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Ischemic Stroke Treatment.
• Acute Ischemic Stroke key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Ischemic Stroke Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Ischemic Stroke market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Acute Ischemic Stroke product details are provided in the report. Download the Acute Ischemic Stroke pipeline report to learn more about the emerging Acute Ischemic Stroke therapies at
https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acute Ischemic Stroke Pipeline Market Drivers
• Increasing prevalence of the disease
• The rising of global health awareness

Acute Ischemic Stroke Pipeline Market Barriers
• Lack of novel Acute Ischemic Stroke therapies

Scope of Acute Ischemic Stroke Pipeline Drug Insight
• Coverage: Global
• Key Acute Ischemic Stroke Companies: Prolong Pharmaceuticals, Meridigen Biotech, Techfields Pharma, Biogen, Shin Poong Pharmaceutical, NuvOx LLC, Acticor Biotech, Acticor Biotech, Athersys, NoNO, and others
• Key Acute Ischemic Stroke Therapies: PP 007, UMC 119 06, TF 0023, BIIB131, SP-8203, NVX-108, Glenzocimab, Invimestrocel, Nerinetide, and others
• Acute Ischemic Stroke Therapeutic Assessment: Acute Ischemic Stroke current marketed and Acute Ischemic Stroke emerging therapies
• Acute Ischemic Stroke Market Dynamics: Acute Ischemic Stroke market drivers and Acute Ischemic Stroke market barriers

Request for Sample PDF Report for Acute Ischemic Stroke Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Acute Ischemic Stroke Report Introduction
2 Acute Ischemic Stroke Executive Summary
3 Acute Ischemic Stroke Overview
4 Acute Ischemic Stroke- Analytical Perspective In-depth Commercial Assessment
5 Acute Ischemic Stroke Pipeline Therapeutics
6 Acute Ischemic Stroke Late Stage Products (Phase II/III)
7 Acute Ischemic Stroke Mid Stage Products (Phase II)
8 Acute Ischemic Stroke Early Stage Products (Phase I)
9 Acute Ischemic Stroke Preclinical Stage Products
10 Acute Ischemic Stroke Therapeutics Assessment
11 Acute Ischemic Stroke Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Acute Ischemic Stroke Key Companies
14 Acute Ischemic Stroke Key Products
15 Acute Ischemic Stroke Unmet Needs
16 Acute Ischemic Stroke Market Drivers and Barriers
17 Acute Ischemic Stroke Future Perspectives and Conclusion
18 Acute Ischemic Stroke Analyst Views
19 Appendix
20 About DelveInsight

Download Sample PDF Report to know more about Acute Ischemic Stroke drugs and therapies- https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Acute Ischemic Stroke Market https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's 'Acute Ischemic Stroke-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Acute Ischemic Stroke Epidemiology https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Acute Ischemic Stroke Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Diagnostic Imaging Equipment Market
https://www.delveinsight.com/report-store/diagnostic-imaging-equipment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.


Invasive Candidiasis Market
https://www.delveinsight.com/report-store/invasive-candidiasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

"DelveInsight's 'Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW.


Sialidosis Market
https://www.delveinsight.com/report-store/sialidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology, and the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Filgrastim Biosimilar Insight
https://www.delveinsight.com/report-store/filgrastim-biosimilar-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's, "Filgrastim Biosimilar Insight, 2022," report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.


Pain Management Devices Market
https://www.delveinsight.com/report-store/pain-management-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027

To know more about our Competitive Services, Click here:
https://www.delveinsight.com/consulting/competitive-intelligence-services?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.